GlaxoSmithKline Pakistan Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0001301016
PKR
384.32
6.82 (1.81%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 15.50

 
2

The company has declared Positive results for the last 4 consecutive quarters

3

With ROE of 26.6, it has a attractive valuation with a 4 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 122,537 Million (Large Cap)

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

3.90%

stock-summary
Debt Equity

-0.24

stock-summary
Return on Equity

30.90%

stock-summary
Price to Book

4.12

Revenue and Profits:
Net Sales:
15,580 Million
(Quarterly Results - Mar 2025)
Net Profit:
2,127 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.23%
0%
-2.23%
6 Months
0.96%
0%
0.96%
1 Year
193.62%
0%
193.62%
2 Years
382.87%
0%
382.87%
3 Years
215.27%
0%
215.27%
4 Years
131.41%
0%
131.41%
5 Years
110.72%
0%
110.72%

GlaxoSmithKline Pakistan Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
10.70%
EBIT Growth (5y)
30.01%
EBIT to Interest (avg)
15.50
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
2.23
Tax Ratio
37.88%
Dividend Payout Ratio
48.72%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
25.87%
ROE (avg)
16.75%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
4.68
EV to EBIT
9.57
EV to EBITDA
8.78
EV to Capital Employed
5.73
EV to Sales
2.08
PEG Ratio
0.06
Dividend Yield
3.49%
ROCE (Latest)
59.85%
ROE (Latest)
30.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -11.40% vs 19.38% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -28.03% vs 53.33% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15,580.10",
          "val2": "17,585.60",
          "chgp": "-11.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4,063.10",
          "val2": "4,282.30",
          "chgp": "-5.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "114.10",
          "val2": "71.00",
          "chgp": "60.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,126.50",
          "val2": "2,954.80",
          "chgp": "-28.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "240.30%",
          "val2": "226.70%",
          "chgp": "1.36%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 23.21% vs 18.69% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1,123.97% vs -78.32% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "61,187.50",
          "val2": "49,661.30",
          "chgp": "23.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9,204.10",
          "val2": "-2,371.50",
          "chgp": "488.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "91.70",
          "val2": "63.00",
          "chgp": "45.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.00",
          "val2": "-152.70",
          "chgp": "84.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6,536.00",
          "val2": "534.00",
          "chgp": "1,123.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "131.90%",
          "val2": "-66.50%",
          "chgp": "19.84%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQstock-summary
Mar'25
Dec'24
Change(%)
Net Sales
15,580.10
17,585.60
-11.40%
Operating Profit (PBDIT) excl Other Income
4,063.10
4,282.30
-5.12%
Interest
114.10
71.00
60.70%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2,126.50
2,954.80
-28.03%
Operating Profit Margin (Excl OI)
240.30%
226.70%
1.36%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2025 is -11.40% vs 19.38% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -28.03% vs 53.33% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
61,187.50
49,661.30
23.21%
Operating Profit (PBDIT) excl Other Income
9,204.10
-2,371.50
488.11%
Interest
91.70
63.00
45.56%
Exceptional Items
-24.00
-152.70
84.28%
Consolidate Net Profit
6,536.00
534.00
1,123.97%
Operating Profit Margin (Excl OI)
131.90%
-66.50%
19.84%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 23.21% vs 18.69% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 1,123.97% vs -78.32% in Dec 2023

stock-summaryCompany CV
About GlaxoSmithKline Pakistan Ltd. stock-summary
stock-summary
GlaxoSmithKline Pakistan Ltd.
Pharmaceuticals & Biotechnology
GlaxoSmithKline Pakistan Limited is a Pakistan-based pharmaceutical company. The Company is engaged in manufacturing and marketing of research based ethical specialties, other pharmaceutical and consumer products. The Company operates through two segments: Pharmaceuticals and consumer healthcare. The Company's Pharmaceuticals segment includes prescription drugs and vaccines. The Company's consumer healthcare segment includes over-the-counter-medicines, oral care and nutritional care. In Pakistan, the Company deals in anti-infective, respiratory, vaccines, dermatological, analgesics, oncology, urology, central nervous system, allergy, cardiovascular and vitamins therapy areas. The Company's pharmaceutical brands include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol, and consumer healthcare brands, which include Panadol, Horlicks, Sensodyne and ENO. Its vaccines include Synflorix, Infanrix Hexa, Rotarix, Havrix and Priorix Tetra.
Company Coordinates stock-summary
Company Details
Sykes Building, 35-Dockyard Road, West Wharf KARACHI None : 74000
stock-summary
Tel: 92 21 32315478
stock-summary
Registrar Details